RECCHIUTI, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 1.731
EU - Europa 1.248
AS - Asia 508
AF - Africa 9
SA - Sud America 8
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.509
Nazione #
US - Stati Uniti d'America 1.712
IE - Irlanda 243
SE - Svezia 214
CN - Cina 213
IT - Italia 209
UA - Ucraina 181
TR - Turchia 133
GB - Regno Unito 124
FR - Francia 76
IN - India 71
DE - Germania 68
RU - Federazione Russa 41
SG - Singapore 39
FI - Finlandia 31
AT - Austria 20
CA - Canada 19
VN - Vietnam 17
HK - Hong Kong 13
BE - Belgio 11
EG - Egitto 8
IR - Iran 8
NL - Olanda 8
BR - Brasile 6
CZ - Repubblica Ceca 5
AU - Australia 4
ES - Italia 4
JP - Giappone 4
KR - Corea 4
PL - Polonia 3
TW - Taiwan 3
HR - Croazia 2
IL - Israele 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
CH - Svizzera 1
CL - Cile 1
EU - Europa 1
MA - Marocco 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
Totale 3.509
Città #
Chandler 366
Dublin 241
Jacksonville 228
Princeton 109
Ashburn 98
Dearborn 94
Southend 88
Izmir 77
Ann Arbor 74
Wilmington 66
Nanjing 62
New York 59
Boardman 56
Beijing 45
Altamura 41
Chieti 40
Rome 32
Woodbridge 32
Houston 29
Cambridge 28
San Mateo 22
Washington 22
Augusta 21
Nanchang 21
Vienna 20
Singapore 19
Dong Ket 17
Montreal 14
Central 12
Falls Church 12
Brussels 11
Shenyang 11
Jiaxing 10
Seattle 9
Cairo 8
Los Angeles 8
Kunming 7
Changsha 6
Jinan 6
Milan 6
Naples 6
Redwood City 6
Tianjin 6
Hangzhou 5
Hebei 5
Norwalk 5
Prato 5
Toronto 5
Amsterdam 4
Brno 4
Düsseldorf 4
Grevenbroich 4
Helsinki 4
Jundiaí 4
Leawood 4
Munich 4
Napoli 4
Rochester 4
Saint-Saens 4
Tokyo 4
Alba 3
Auburn Hills 3
Dacun 3
Lanciano 3
Lappeenranta 3
Pescara 3
Phoenix 3
Shanghai 3
Taizhou 3
Tappahannock 3
Woburn 3
Aprilia 2
Belgrade 2
Belo Horizonte 2
Campobasso 2
Carinola 2
Chaoyang 2
Chicago 2
Delhi 2
Denver 2
Edinburgh 2
Frankfurt Am Main 2
Fuzhou 2
Hefei 2
Islington 2
Lanzhou 2
Louisville 2
Ness Ziona 2
Orange 2
Piotrkow Trybunalski 2
Recanati 2
Rouen 2
San Cristóbal de La Laguna 2
Sinalunga 2
Tehran 2
Zagreb 2
Adelaide 1
Alessandria 1
Antalya 1
Ardabil 1
Totale 2.305
Nome #
Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection 124
Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicles 119
Mechanisms of endothelial cell dysfunction in cystic fibrosis 119
Establishment and long-term culture of human cystic fibrosis endothelial cells 105
Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. 99
MicroRNA-181b regulates ALX/FPR2 expression and proresolution signaling in human macrophages. 96
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. 95
Lipoxins, resolvins, and the resolution of inflammation 94
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. 93
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. 92
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response 90
Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity 89
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 86
Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. 86
Novel anti-inflammatory--pro-resolving mediators and their receptors. 84
microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. 83
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". 82
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. implications for aspirin 'resistance'. 81
Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins 81
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 76
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 75
Lipoxin receptors 74
HARNESSING RESOLUTION MEDIATORS AS NOVEL THERAPEUTICS FOR CYSTIC FIBROSIS 74
Resolvin D1 promotes resolution of inflammation, infection, and damage in CF 74
Circulating endothelial progenitor cells and low-dose-aspirin-insensitive thromboxane biosynthesis in polycythemia rubra vera. 72
RESOLVIN D1 FOR TARGETING LUNG INFLAMMATION, INFECTION, AND DAMAGE IN CF 72
Homocysteine modulates the CD40/CD40L system 71
RESOLVINS, LIPOXINS, AND MARESINS IN RESOLUTION OF INFLAMMATION 69
Resolvin D1 improves airway inflammation and exercise capacity in cystic fibrosis lung disease. 68
Epigenetic regulation of the formyl peptide receptor 2 gene 68
ACTIONS OF RESOLVIN D1 AND D2 IN CYSTIC FIBROSIS MRSA LUNG INFECTION AND INFLAMMATION 68
PRORESOLVING AND ANTIMICROBIAL BIOACTIONS OF MELANOCORTINS ON CF CELLS 66
Proresolving Lipid Mediators and Receptors in Stem Cell Biology: Concise Review 65
Lipoxins and aspirin-triggered lipoxins in resolution of inflammation 65
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. 64
Resolution of sickle cell disease–associated inflammation and tissue damage with 17R-resolvin D1 64
Resolvin E1 receptor activation signals phosphorylation and phagocytosis. 63
Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis 63
Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. 60
Targeting caveolin-1 deficiency in bone marrow derived cells: A new therapeutic window for fibrotic diseases? 58
Resolvin D1 and its GPCRs in resolution circuits of inflammation. 57
Resolvin D1 and Resolvin D2 Protect Against Hypoxia/Reoxygenation Induced Lung and Kidney Damage in a Sickle Cell Mouse Model of Acute Vaso-Occlusive Crisis 55
Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis 55
Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes 53
PROTECTIVE ROLE OF RVD1 AND ITS RECEPTOR IN CYSTIC FIBROSIS 52
Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. 48
Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. 47
Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages 42
The Resolution Approach to Cystic Fibrosis Inflammation 40
Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer 34
Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen 32
Roles of specialized pro-resolving lipid mediators in autophagy and inflammation 29
Specialized pro-resolving lipid mediators and resolution of viral diseases 22
Resolvins Modulate Netosis and Autoimmunity in Sickle Cell Disease 22
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury 14
Impaired pro-resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease 14
Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy 9
REPURPOSING GALLIUM FOR LOCAL TREATMENT OF BACTERIAL PNEUMONIA THROUGH INHALABLE NANO-EMBEDDED MICROPARTICLES 8
Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis 5
Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice 5
Totale 3.870
Categoria #
all - tutte 14.283
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.283


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020685 178 27 4 23 57 63 89 48 31 90 67 8
2020/2021453 39 9 55 20 33 67 15 14 109 46 15 31
2021/2022344 5 10 2 88 15 11 6 22 19 15 26 125
2022/2023958 72 133 61 105 88 170 49 64 146 12 32 26
2023/2024649 54 32 37 26 35 193 97 55 7 29 19 65
2024/202572 72 0 0 0 0 0 0 0 0 0 0 0
Totale 3.870